


Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer

Rachel B. Forster¹   | Anders Engeland^{2,3}  | Rune Kvåle^{1,4}  | Vidar Hjellvik²  | Tone Bjørge^{3,5} 

¹Department of Health Registry Research and Development, Norwegian Institute of Public Health, Bergen, Norway

²Department of Chronic diseases, Norwegian Institute of Public Health, Oslo, Norway

³Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

⁴Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway

⁵Cancer Registry of Norway, Oslo, Norway

Correspondence

Rachel B. Forster, Department of Health Registry Research and Development, Norwegian Institute of Public Health, Bergen, Norway.

Email: rachel.forster@fhi.no

Funding information

Kreftforeningen, Grant/Award Numbers: 08154-2019, 182360-2016

Abstract

Studies have suggested that prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) are at increased risk of developing or exacerbating cardiovascular disease (CVD). We aimed to explore the association between ADT for PCa and subsequent CVD and all-cause mortality in this nationwide, longitudinal study. We also evaluated the role of cardiovascular risk and ADT duration to determine effect modification. Norwegian registry data were used to identify patients with PCa from 2008-18 and who received primary ADT in the first year after diagnosis. The associations between ADT and composite cardiovascular events, and the individual components of myocardial infarction, stroke and heart failure, in addition to atrial fibrillation and all-cause mortality, were explored using time-varying Cox regression models. We included 30 923 PCa patients, of whom 8449 (27%) received primary ADT. Mean follow-up was 2.9 and 3.8 years for CVD events and mortality, respectively. We found an association between ADT and composite CVD (adjusted HR 1.13: 95% CI 1.05-1.21), myocardial infarction (1.18: 1.05-1.32), stroke (1.21: 1.06-1.38), heart failure (1.23: 1.13-1.35) and all-cause mortality (1.49: 1.39-1.61). These associations persisted in those with low and moderate CVD risk and ADT longer than 7 months. A relationship between ADT and composite CVD and all-cause mortality was observed, especially in those with moderate CVD risk and longer treatment duration. Future studies with more detailed cancer data are needed to verify the clinical relevance of these results, especially when considering all-cause mortality within the context of treatment guidelines and benefits of ADT.

KEYWORDS

androgen deprivation therapy, cardiovascular disease, epidemiology, prostate cancer

Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; CVD, cardiovascular disease; EAU, European Association of Urology; HR, hazard ratio; LHRH, leutenizing hormone-releasing hormone; NorPD, Norwegian Prescription Database; NTproBNP, N-terminal pro-B-type natriuretic peptide; PCa, prostate cancer.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *International Journal of Cancer* published by John Wiley & Sons Ltd on behalf of UICC.

What's new?

Existing evidence suggests that prostate cancer patients receiving androgen deprivation therapy are at increased risk of cardiovascular disease. The relationship between prostate cancer treatment and cardiovascular disease remains unclear, however. Using longitudinal registry data for all prostate cancer patients in Norway, our study identifies an increased risk of cardiovascular disease and mortality in patients treated with androgen deprivation therapy. The increased risk is most pronounced in patients with low or moderate prior risk of cardiovascular disease and longer duration of treatment. The findings contribute new evidence to the ongoing discussion about the use of hormonal therapy.

1 | INTRODUCTION

Prostate cancer (PCa) patients have increased risk of developing cardiovascular disease (CVD) and are more likely to die from non-PCa specific causes, mainly cardiovascular related, than from PCa^{1,2} There is evidence that androgen deprivation therapy (ADT), a common treatment for more aggressive PCa, may increase the risk of cardiovascular morbidity and mortality, as well as all-cause mortality.²⁻⁶ However, there have been contradictory findings of the relationship between PCa treatment and CVD.⁷⁻¹⁰

Contradictory findings come mainly from randomised controlled trials which historically include healthier patients than the general population and may not reflect real-world experiences.¹¹ The hypothesis that increased risk of CVD after ADT disproportionately affects those with preexisting CVD is reflected in studies that have shown increased risk of all-cause mortality after treatment with ADT only in those with a higher burden of CVD comorbidity.^{12,13} Also, studies showing no association between ADT and adverse health outcomes have mainly focused on all-cause mortality or fatal CVD rather than nonfatal CVD events. Thus, they cannot directly provide evidence on whether ADT increases the risk of nonfatal CVD.⁷⁻⁹

ADT has been a cornerstone of treatment for PCa for decades, with an aim to deprive androgen-dependent prostate cancer cells of circulating androgen and its precursors.¹⁴ This treatment is currently recommended as monotherapy or in combination with other therapeutics for aggressive and more advanced cancers and has shown to be greatly beneficial at reducing cancer related death, but also the cause of some significant side effects.^{15,16} It is therefore imperative to determine if this critical treatment option is contributing to increased risk of CVD, especially in those with higher risk of CVD, and determine if there are appropriate treatment recommendation modifications that should be made to mitigate this risk.

The aim of our study was to use longitudinal Norwegian health registry data that reflects real-life application in a nationwide cohort of PCa patients to explore the association between primary medication-based ADT for PCa and subsequent CVD and all-cause mortality. We also aimed to evaluate the role of cardiovascular risk prior to PCa to determine effect modification by CVD risk, as well as ADT duration.

2 | METHODS

2.1 | Study population

This is a registry-based, longitudinal cohort study using nationwide data from Norway (population 2.0 million males above age 20 years in 2018). A unique national ID number for all residents in Norway allowed for comprehensive, encrypted linkage between the registries.

Data on PCa diagnosis were extracted from the Cancer Registry of Norway (1953-2018, data from 1953 to 2007 was used to determine prior cancers), reimbursed prescription data was sourced from the Norwegian Prescription Database (NorPD) (2004-2019, with diagnosis codes included from 2008), the Norwegian Patient Registry provided specialist health care data (2008-2018), the National Population Registry provided data on emigration and deaths (2005-2019), and the Norwegian National Education Database provided information on highest education achieved (2004, 2009 and 2014).

The cohort included all males born during 1924-1990, alive and living in Norway on 1 January 2009, and with PCa diagnosed 2008-2018 and no other cancer diagnosis prior to PCa. For this analysis, we have restricted our population to PCa diagnosis years 2008-2017 (CVD outcomes) or 2008-2018 (mortality). We relied on the Norwegian Patient Registry and NorPD to derive risk factors and CVD outcomes, which holds individual level data from 2008. This is also the year the prescription data began including reimbursement codes corresponding to diagnoses.

Patients were excluded if they had a cancer morphology not consistent with malignant adenocarcinomas of the prostate, evidence of distant metastases at diagnosis or unknown stage, if they had less than 1 year of follow-up, if they received primary treatment (within the first year of diagnosis) with abiraterone or enzalutamide, or any ADT prior to their PCa diagnosis.

The ADT group included patients that received primary treatment with a luteinizing hormone-releasing hormone (LHRH) agonist (buserelin, leuprorelin, goserelin, triptorelin or histrelin) or LHRH antagonists (degarelix or abarelix) within the first year after diagnosis. The treatment group was compared to PCa patients that did not receive ADT within the first year.

2.2 | Follow-up and outcomes

Follow-up began 1 year after PCa diagnosis and continued until one of the following: a CVD outcome (listed below), death, emigration, aged over 85 years or end of study on 31 December 2018 for CVD outcomes and 31 December 2019 for all-cause mortality. If the specific CVD outcome occurred in the year between PCa diagnosis and when the follow-up started, that patient was excluded from the analysis.

Cardiovascular and mortality outcomes included (full definitions using diagnostics codes are provided in Supplemental A):

1. Composite CVD (myocardial infarction, stroke and/or heart failure).
2. Myocardial infarction.
3. Stroke.
4. Heart failure.
5. Atrial fibrillation.
6. All-cause mortality.

2.3 | Covariates

Other variables we included in our statistical models were age (continuous) at PCa diagnosis, cancer stage (local or regional),

highest education level completed at diagnosis (compulsory, intermediate, tertiary), year of PCa diagnosis (2008-2010, 2011-2013, 2014-2017/2018) and the presence of CVD risk factors in the year prior to PCa diagnosis: Hypertension, hypercholesterolemia, atrial fibrillation, heart failure, myocardial infarction, stroke or diabetes. Further information on the definition of the CVD risk factor variables can be found in Supplemental A.

We also created a prescription-based comorbidity index using prescription data from the 4 years prior to PCa diagnosis (Supplemental B), based on methods developed by Häppölä et al., to account for multimorbidity.¹⁷ The original study found the score to perform similarly to the Charlson comorbidity index, but not be reliant on extensive clinical information. We validated the derived index with all-cause mortality and found a consistent, positive association. The comorbidity index was created as a continuous variable that ranged from -4 to 9 in our population but then used in analysis as a categorical variable: <0 , 0 , $1-4$ or ≥ 5 .

2.4 | Statistical analysis

Cox proportional hazards regression models with time since diagnosis as a time-variable were used to estimate the association between




FIGURE 1 Selection of the study population (including cancer-free males living in Norway January 1st, 2008) [Color figure can be viewed at wileyonlinelibrary.com]

ADT and the CVD outcomes and all-cause mortality, reporting hazard ratios (HRs) and 95% confidence intervals (CIs).

The fully adjusted multivariable models included ADT status (treated/not treated), age at PCa diagnosis, stage, year of PCa diagnosis, education, comorbidity index and CVD risk factors in the year prior to PCa diagnosis: hypertension, hypercholesterolemia, diabetes, atrial fibrillation, heart failure, myocardial infarction and stroke.

Next, we wanted to explore the impact of CVD risk at the time of PCa diagnosis more thoroughly. A statistical model with covariates

corresponding to the fully adjusted model above, but without the CVD risk factors included was constructed, and was stratified by the CVD risk groups based on risk factors present in the year prior to PCa diagnosis:

- Low risk:
 - No evidence of prior CVD event (myocardial infarction, stroke, heart failure), no hypertension, no hypercholesterolemia, no diabetes.

TABLE 1 Study characteristics at time of prostate cancer diagnosis

| | Total (n = 30 923) | ADT (n = 8449) | No ADT (n = 22 474) |
|------------------------------------|--------------------|----------------|---------------------|
| Mean age at diagnosis (years [SD]) | 67.4 (7.6) | 70.8 (6.8) | 66.1 (7.5) |
| Age at diagnosis (years) | | | |
| <60 | 5243 (17.0%) | 563 (6.7%) | 4680 (20.8%) |
| 60-64 | 6260 (20.2%) | 1122 (13.3%) | 5138 (22.9%) |
| 65-69 | 8130 (26.3%) | 1962 (23.2%) | 6168 (27.4%) |
| 70-84 | 11 290 (36.5%) | 4802 (56.8%) | 6488 (28.9%) |
| Stage | | | |
| Local | 19 983 (64.4%) | 3595 (42.5%) | 16 388 (72.9%) |
| Regional | 10 940 (35.4%) | 4854 (57.5%) | 6086 (27.1%) |
| Education level ^a | | | |
| Compulsory | 6659 (21.5%) | 2262 (26.8%) | 4397 (19.6%) |
| Intermediate | 15 825 (51.2%) | 4326 (51.2%) | 11 499 (51.2%) |
| Tertiary | 8319 (26.9%) | 1820 (21.5%) | 6499 (28.9%) |
| Unknown | 120 (0.4%) | 41 (0.5%) | 79 (0.4%) |
| Comorbidity score | | | |
| <0 | 3954 (12.8%) | 949 (11.2%) | 3005 (13.4%) |
| 0 | 16 438 (53.2%) | 3976 (47.1%) | 12 462 (55.5%) |
| 1-4 | 10 274 (33.2%) | 3412 (40.4%) | 6862 (30.5%) |
| 5+ | 257 (0.8%) | 112 (1.3%) | 145 (0.6%) |
| Year of prostate cancer diagnosis | | | |
| 2008-2010 | 7145 (23.1%) | 2255 (26.7%) | 4890 (21.8%) |
| 2011-2013 | 9485 (30.7%) | 2723 (32.2%) | 6762 (30.1%) |
| 2014-2018 | 14 293 (46.2%) | 3471 (41.1%) | 10 822 (48.2%) |
| Hypertension (yes) | 15 710 (50.8%) | 4891 (57.9%) | 10 819 (48.1%) |
| High cholesterol (yes) | 10 566 (34.2%) | 3348 (39.6%) | 7218 (32.1%) |
| Diabetes | 2922 (9.4%) | 1009 (11.9%) | 1913 (8.5%) |
| Heart failure | 1640 (5.3%) | 615 (7.3%) | 1025 (4.6%) |
| Atrial fibrillation | 2553 (8.3%) | 938 (11.1%) | 1615 (7.2%) |
| Myocardial infarction | 1210 (3.9%) | 415 (4.9%) | 795 (3.5%) |
| Stroke | 853 (2.8%) | 343 (4.1%) | 510 (2.3%) |
| CVD risk | | | |
| Low | 12 508 (40.4%) | 2841 (33.6%) | 9667 (43.0%) |
| Medium | 15 242 (49.3%) | 4433 (52.5%) | 10 809 (48.1%) |
| High | 3173 (10.3%) | 1175 (13.9%) | 1998 (8.9%) |

Abbreviations: ADT, androgen deprivation therapy; CVD, cardiovascular disease.

^aCategorisation based on information from Statistics Norway; information from 2004 was used for men diagnosed in 2008, information from 2009 was used for men diagnosed in 2009-2013 and information from 2014 was used for men diagnosed in 2014-2018.

- Medium risk:
 - Hypertension.
 - AND/OR hypercholesterolemia.
 - AND/OR diabetes.
 - AND NO stroke or myocardial infarction or heart failure.
- High risk:
 - Prior stroke.
 - AND/OR myocardial infarction.
 - AND/OR heart failure.

We also evaluated the impact of duration of ADT by including the ADT variable as <7 months, 7-18 months and >18 months compared to no use, as a time-varying covariate. Duration of ADT was determined by prescription patterns, where duration of continuous prescriptions was added together. If there was longer than 6 months between one prescription and the following the treatment period was ended. Six months is the longest duration possible on a single prescription for most of the various treatment options in our study (Supplemental C).

A final set of models were conducted incorporating CVD risk and ADT duration groups. Sensitivity analysis was performed by removing people diagnosed with PCa in 2008 to make sure possible missing

CVD risk factor data in this group did not affect the outcomes. Additional post hoc sensitivity analysis was performed on the models stratified by CVD risk by removing patients in the ADT treatment group that received LHRH antagonist medications. All analyses were performed using SPSS (version 27) and STATA (version 15.0) software.

3 | RESULTS

A total of 43 835 males born during 1924-1990, aged 37-84, were diagnosed with PCa during 2008-2018 with no prior cancer diagnoses, and after applying the exclusion criteria 30 923 were included in the cohort (Figure 1). Of these, 8449 received ADT in the first year after PCa diagnosis.

From Table 1, the mean age of the whole study population was 67.4 years, while those that received ADT were slightly older at 70.8 years than those that did not receive primary ADT (66.1 years). Most patients that received ADT had regional disease where most that did not had localised disease. Highest educational level achieved was roughly similar between the two groups while there appeared to be higher proportions of comorbidity in the ADT group, which was also demonstrated in the proportion of CVD risk factors.

TABLE 2 Risk of cardiovascular disease and death after hormonal treatment for prostate cancer

| Outcome | Age-adjusted HR (95% CI) | Full multivariable ^a HR (95% CI) | Low CVD risk ^b HR (95% CI) | Moderate CVD risk ^b HR (95% CI) | High CVD risk ^b HR (95% CI) |
|-----------------------|--------------------------|---|---------------------------------------|--|--|
| Composite CVD | 1.17 (1.09-1.25) | 1.13 (1.05-1.21) | 1.17 (1.03-1.33) | 1.11 (1.02-1.21) | 1.29 (0.92-1.82) |
| Myocardial infarction | 1.23 (1.10-1.38) | 1.18 (1.05-1.32) | 1.24 (0.97-1.57) | 1.17 (1.01-1.36) | 1.13 (0.83-1.54) |
| Stroke | 1.23 (1.08-1.40) | 1.21 (1.06-1.38) | 1.23 (0.96-1.58) | 1.13 (0.95-1.35) | 1.42 (1.01-2.00) |
| Heart failure | 1.36 (1.24-1.48) | 1.23 (1.13-1.35) | 1.30 (1.06-1.58) | 1.23 (1.10-1.37) | 1.38 (1.04-1.84) |
| Atrial fibrillation | 1.06 (0.97-1.16) | 1.03 (0.94-1.13) | 0.96 (0.80-1.14) | 1.04 (0.92-1.17) | 1.10 (0.85-1.42) |
| All-cause mortality | 1.78 (1.65-1.91) | 1.49 (1.38-1.61) | 1.75 (1.52-2.01) | 1.50 (1.35-1.66) | 1.17 (0.98-1.39) |

Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; PCa, prostate cancer.

^aCovariates in model (whole population): Treatment status (hormonal treatment/no hormonal treatment) + age at PCa diagnosis, period of diagnosis, cancer stage, education, comorbidity index, hypertension, high cholesterol, diabetes, atrial fibrillation, heart failure, myocardial infarction, stroke.

^bCovariates in model (stratified by CVD risk): Treatment status (hormonal treatment/no hormonal treatment) + age at PCa diagnosis, period of diagnosis, cancer stage, education, comorbidity index (CVD risk factors used to define risk groups).

TABLE 3 Risk of cardiovascular disease and death after hormonal treatment for prostate cancer by duration of hormonal treatment

| Outcome | ADT <7 months HR (95% CI) | ADT 7-18 months HR (95% CI) | ADT >18 months HR (95% CI) |
|-----------------------|---------------------------|-----------------------------|----------------------------|
| Composite CVD | 1.07 (0.93-1.23) | 1.12 (1.03-1.22) | 1.23 (1.09-1.38) |
| Myocardial infarction | 1.10 (0.88-1.38) | 1.14 (0.99-1.31) | 1.31 (1.08-1.60) |
| Stroke | 1.09 (0.85-1.41) | 1.32 (1.14-1.54) | 1.03 (0.81-1.30) |
| Heart failure | 1.14 (0.96-1.36) | 1.25 (1.13-1.39) | 1.28 (1.09-1.49) |
| Atrial fibrillation | 1.00 (0.83-1.20) | 1.00 (0.90-1.12) | 1.18 (1.01-1.37) |
| All-cause mortality | 1.52 (1.34-1.74) | 1.35 (1.23-1.47) | 2.04 (1.83-2.27) |

Note: Model includes age, period of diagnosis, cancer stage, education, comorbidity index and CVD risk factors (hypertension, high cholesterol, diabetes, atrial fibrillation, heart failure, myocardial infarction, stroke).

Abbreviations: ADT, androgen deprivation treatment (hormonal treatment); CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.

By the end of the study 4445 (14%) experienced a first CVD outcome during follow-up (2009-2017), 3360 (11%) died (2009-2018), 53 (0.2%) had emigrated and 2103 (6.8%) were censored at 85 years. The mean follow-up was 2.9 years (range 0-10) for those that experienced a CVD outcome during follow-up and 3.8 years (range 0-11) for those that died.

For the patients that received ADT in the first year after PCa diagnosis, 1460 (17%) had less than 7 months of hormonal treatment, 4755 (56%) had 7-18 months and 2234 (26%) had more than 18 months.

3.1 | Association between ADT and CVD and death by CVD risk groups

In the fully adjusted model, there was an association between ADT and increased risk of composite CVD with an HR of 1.13 (95% CI 1.05-1.21), and this association was maintained in both the low and moderate CVD risk groups, and in the high CVD risk group a stronger association was indicated but not statistically significant (Table 2). There was also an association between ADT and risk of each of the component CVD outcomes that made up the composite CVD in the fully adjusted model: Myocardial infarction HR 1.18 (1.05-1.32), stroke HR 1.21 (1.06-1.38) and heart failure HR 1.23 (1.13-1.35). These associations varied based on CVD risk groupings. There was no association with myocardial infarction in the low and high-risk groups, but there was in the moderate CVD risk group (HR 1.17, 1.01-1.36). There was also no association with stroke in the low and moderate-risk groups, but there was an association in the high-risk group: HR 1.42 (1.01-2.00). Hormonal treatment and heart failure were associated across all three CVD risk groups: HR 1.30 (1.06-1.58), 1.23 (1.10-1.37) and 1.38 (1.04-1.84), respectively.

In addition, all-cause mortality was significantly increased in the ADT group with a HR of 1.49 (1.38-1.61) in the fully adjusted multi-variable model, as well as for each individual CVD risk group. There was no association between ADT and atrial fibrillation during the study period (HR 1.03: 0.94-1.13).

3.2 | Association between ADT and CVD and death, accounting for ADT duration

In the fully adjusted models, there were no associations between ADT <7 months and composite CVD or the individual events. However, there were associations between ADT lasting 7-18 months and composite CVD, stroke and heart failure: HR 1.12 (1.03-1.22), 1.32 (1.14-1.54) and 1.25 (1.13-1.39), respectively (Table 3). There was also an increased risk in composite CVD, myocardial infarction and stroke in the ADT group that received treatment over 18 months (HR 1.23 [1.09-1.38], 1.31 [1.08-1.60] and 1.28 [1.09-1.49], respectively). There was also an association between >18 months treatment and atrial fibrillation, HR 1.18 (1.01-1.37).

TABLE 4 Risk of cardiovascular disease and death after hormonal treatment for prostate cancer stratified by duration of hormonal treatment and cardiovascular risk at prostate cancer diagnosis

| Outcome | Low CVD risk HR (95% CI) | | | Moderate CVD risk HR (95% CI) | | | High CVD risk HR (95% CI) | | |
|-----------------------|--------------------------|------------------|------------------|-------------------------------|------------------|------------------|---------------------------|------------------|------------------|
| | <7 months | 7-18 months | >18 months | <7 months | 7-18 months | >18 months | <7 months | 7-18 months | >18 months |
| Composite CVD | 1.08 (0.85-1.39) | 1.16 (0.99-1.35) | 1.38 (1.13-1.68) | 1.02 (0.86-1.20) | 1.09 (0.98-1.21) | 1.17 (1.01-1.36) | 1.41 (0.79-2.52) | 1.25 (0.88-1.79) | 0.60 (0.29-1.65) |
| Myocardial infarction | 1.18 (0.74-1.89) | 1.14 (0.84-1.54) | 1.53 (1.06-2.21) | 1.03 (0.76-1.39) | 1.16 (0.97-1.39) | 1.27 (0.98-1.64) | 1.26 (0.74-2.16) | 1.10 (0.78-1.55) | 0.98 (0.56-1.74) |
| Stroke | 0.94 (0.56-1.59) | 1.43 (1.07-1.92) | 1.06 (0.69-1.62) | 1.22 (0.89-1.67) | 1.21 (0.99-1.48) | 0.85 (0.61-1.18) | 0.91 (0.42-1.96) | 1.49 (1.02-2.18) | 1.64 (0.91-2.97) |
| Heart failure | 1.60 (1.14-1.24) | 1.19 (0.93-1.52) | 1.40 (1.03-1.89) | 1.06 (0.86-1.32) | 1.29 (1.14-1.46) | 1.24 (1.03-1.49) | 1.11 (0.60-2.05) | 1.37 (1.00-1.88) | 1.57 (0.94-2.63) |
| Atrial fibrillation | 1.03 (0.74-1.44) | 0.86 (0.68-1.07) | 1.19 (0.90-1.57) | 1.01 (0.79-1.28) | 1.02 (0.88-1.17) | 1.16 (0.94-1.42) | 0.82 (0.47-1.45) | 1.17 (0.87-1.56) | 1.18 (0.78-1.80) |
| All-cause mortality | 1.59 (1.23-2.05) | 1.49 (1.26-1.77) | 2.63 (2.19-3.17) | 1.52 (1.27-1.82) | 1.39 (1.23-1.57) | 1.97 (1.69-2.29) | 1.48 (1.11-1.97) | 1.06 (0.86-1.30) | 1.43 (1.08-1.88) |

Note: Model includes age, period of diagnosis, cancer stage, education, comorbidity index. Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; PCa, prostate cancer.

All three treatment durations were associated with all-cause mortality: <7 months HR 1.52 (1.34-1.74), 7-18 months HR 1.35 (1.23-1.47) and >18 months HR 2.04 (1.83-2.27).

3.3 | Association between ADT (accounting for duration) and CVD and death, stratified by CVD risk at PCa diagnosis

When we further stratified our analysis by CVD risk at time of PCa diagnosis as either low-, moderate- or high-risk and ADT duration, we found an association with composite CVD for both low- and moderate-risk CVD only in the >18 months ADT group (Table 4). Risk of myocardial infarction was also increased in the low CVD risk group in those that received ADT more than 18 months. Increased risk of heart failure was observed in the low-risk group for <7 months and >18 months treatment duration, as well as in the moderate risk group for 7-18 and >18 months, and only in the 7-18 months duration group for high CVD risk. There remained an association for all durations of ADT and risk CVD groups with all-cause mortality except for 7-18 months duration in the high CVD risk group.

3.4 | Additional sensitivity analysis

We performed a sensitivity analysis by removing patients that were diagnosed in the year 2008, as some of the patients may not have complete CVD risk factor data in the 1-year period before PCa diagnosis. There was very little change in the HRs and CIs. There was also no change in the results of models evaluating CVD risk when patients that received LHRH antagonists were removed (data not shown).

4 | DISCUSSION

In our study of 30 923 patients with prostate cancer, 8449 received ADT as primary treatment within the first year of diagnosis. We identified an association between hormonal treatment and the composite CVD outcome, as well as the individual components myocardial infarction, stroke and heart failure. The association with the composite outcome was maintained in the low and moderate CVD risk groups. A stronger association was indicated in the high CVD risk group but was not statistically significant.

When we evaluated ADT based on duration (<7 months, 7-18 months and 18+ months) the most prominent associations were in those with 18+ months ADT. When the analysis was stratified by ADT duration and CVD risk, there remained an association between ADT and composite CVD in the low-risk and moderate-risk groups, but only with the longest ADT duration. However, the stratified analyses often had lower numbers, so these analyses cannot clearly reject an association, due to lack of power.

Our interpretation of the lack of statistical significance in the high-risk CVD group for the composite CVD outcome is mainly that

there was a lack of power. There was a higher point estimate but wider confidence interval, and the number of patients in this group was significantly lower than the other two risk groups. Although Table 1 does indicate higher rates of CVD risk factors, and therefore treatment for these risk factors, we do not believe this was a strong factor in the high-risk CVD group as there were high rates of both antihypertensive and antihypercholesterolemia medical treatment in this population that did not differ by ADT treatment status. To further evaluate possible confounding and bias in this analysis, we removed the small proportion of patients that received LHRH antagonists in post hoc sensitivity analysis to determine if this could have been a contributing factor, but there were no changes found in the interpretation of the results.

When interpreting the findings around duration of ADT treatment, we want to focus on the fact that the effect modification by treatment duration is likely because those receiving ADT for longer durations have a more severe form of PCa than those with shorter durations. Therefore, these findings could indicate the increased risk of CVD is reflective of an unhealthier population and not the treatment, despite controlling for comorbidity and cardiovascular risk factors.

We consistently identified an association between ADT and all-cause mortality for all risk group and treatment durations, but caution interpretation of these findings as a direct cause of the treatment, due to the presence residual confounding of PCa severity not only being possible, but likely.

Our study benefits from nation-wide registry data of high quality and contributes to a growing research field that seeks to identify sub-populations of people with PCa that may be at higher risk of CVD after treatment with ADT. Due to the nature of population-wide data the findings have strong external generalisability. The study included 10 years of data for 30 923 PCa patients, with linkages between several health and sociodemographic registries to provide a rich amount of information. Data from the Cancer Registry of Norway, used to define the population, the Norwegian Prescription Database, used to create the treatment groups and risk factors, and the Norwegian Patient Registry, to identify outcomes, are of superior quality in terms of completeness and correctness.¹⁸⁻²¹ This strength in data and large study size is reflected in the relatively narrow confidence intervals even when conducting stratified analysis of smaller groups.

One main concern was confounding by indication as PCa patients that have more advanced cancer and thus poorer overall survival, are more likely to receive ADT. These patients may also have a high burden of CVD risk factors, therefore complicating the ability to clearly determine an association.^{22,23} Our main concern is for the mortality outcome and less for the cardiovascular disease outcomes as we used detailed diagnosis codes and medications to control for previous risk factors. Although we did not have access to cancer data specific to aggressiveness, other than stage, that would help to address this better, such as Gleason score or TNM staging, we attempted to address this bias concern by controlling for stage, comorbidity and specific CVD risk factors. In addition, treatment duration can be considered an indicator of disease severity as current guidelines have longer durations of hormonal treatment as severity increases.²⁴

Despite efforts to control for confounding by indication, we believe there remained a lack of health status characterisation which has prohibited full understanding of the effect of the treatment, specifically for the all-cause mortality outcome. This problem would be a concern for most studies evaluating this research question as even if one had increased data to better characterise the population, patients that receive ADT would inherently be an unhealthier population as it is a treatment recommended in more severe forms of PCa. Future studies should focus on a narrower population with advanced forms of the disease to create balanced exposure groups based on PCa diagnostic variables including Gleason score, TNM and stage, as well as cardiovascular risk factors and multimorbidity scoring. Propensity score matching may be an alternative design approach for observational studies evaluating, such as was done in a Korean study evaluating the impact of ADT on cerebral infarction.²⁵

Additionally, we tried to reduce the risk of overt immortal time bias by requiring at least 1 year of follow-up after diagnosis to account for waiting time before treatment started.²⁶ While this method did allow sufficient time for patients to begin primary treatment there was an inevitable loss of outcome events within the first year after diagnosis (1 death and 1048 composite CVD events). Therefore, our analysis was evaluating longer term outcomes rather than those related to initial treatment onset. In addition, treatment duration was included as a time-varying variable in the appropriate analyses.

Other possible concerns include relying on prescription data without evidence of adherence, not having data on smoking status, which is an important risk factor for CVD, but we did include education status and multimorbidity, which can capture some of the residual variation due to smoking. Also, there may be confounding by concomitant treatments, which we could not control for as we did not have data on other PCa treatments such as prostatectomy or radiotherapy. Rates of orchiectomy, as a surgical form of ADT, for primary treatment of PCa are very low in Norway, so we were not concerned with treatment bias.²⁷ Finally, some of the stratified analyses had small numbers, which should be considered when interpreting the results.

A study from Sweden, based on national registry data, compared cardiovascular outcomes in people with PCa that received ADT to a PCa-free population and found use of GnRH agonists to be associated with incident CVD events.²⁸ This association was maintained in those without previous CVD and was stronger in those that had a history of CVD.

An observational study from Taiwan, which also aimed to evaluate the difference in survival benefit based on baseline CVD after ADT, found that ADT had an overall benefit on survival, but not for patients with prior CVD.²⁹ Our study consisted of 3835 patients aged 65 and above with aggressive PCa, many with metastatic disease, which we excluded in our analyses.

Keating et al. evaluated the risk of myocardial infarction in a large, observational study of 185 106 people with local or regional PCa and found an association between ADT and the outcome, which was stronger in those with baseline CVD.³⁰ However, they also found increased risk of myocardial infarction in those that did not receive

ADT but had baseline CVD. The authors concluded there was no evidence that the excess risk of myocardial infarction in the ADT group was not modified by preexisting CVD and therefore treatment with ADT should not be based on preexisting risk, which disagrees with our own findings. Similarly, our study does not have congruent findings with two other studies that identified increased risk of all-cause mortality in those with previous myocardial infarction or stroke¹² or heart failure or myocardial infarction.¹³

A recent observational study from South Korea displayed findings contradictory to ours, but our study excluded patients with prior CVD, which constitutes a significant population.¹⁰ Also, their findings that ADT may reduce the risk of CVD in people that received ADT for more than 2 years demonstrate that in people with aggressive disease that require long-term ADT, this type of treatment is necessary to prevent cancer specific mortality and not necessarily that ADT is cardio-protective.

It remains not fully understood how ADT may directly cause serious cardiovascular events, but there is evidence that ADT has a detrimental metabolic impact, can decrease insulin sensitivity and lead to dyslipidemia.^{16,31,32} A recent prospective study from China on 60 patients with PCa demonstrated ADT to have a significant impact on BMI, waist to hip ratio, body fat percentage and HDL cholesterol and metabolic syndrome, all important risk factors for CVD.³³ A post hoc analysis from trial data provided evidence to support a decrease in levels of several proteins associated with plaque instability in participants that received LHRH agonists, and therefore can possibly lead to increased risk of plaque rupture.³⁴

The use of ADT in treatment for advanced and aggressive PCa serves a very important role with clear evidence from phase III randomised controlled trials that the use of ADT in combination with radiotherapy, has definitive superiority to radiotherapy alone for survival and disease progression.³⁵⁻³⁷ Although there is evidence of ADT being associated with increased risk of CVD and all-cause mortality, it cannot simply be removed as a treatment option. Rather, risk reduction and mitigation strategies should be explored, specifically for subgroups of people at moderate risk of CVD.

Most importantly, there should be a focus on using clear guidelines to recommend ADT only to patients that have a demonstrated benefit from the treatment.²⁹ An Italian cohort study demonstrated that roughly a quarter of their study population of people with PCa that were treated with ADT should not have been offered the treatment according to the European Association of Urology (EAU) guidelines.³⁸ This group of patients treated with ADT discordant with EAU guidelines were also more at risk of CVD outcomes.

If a patient is at higher risk of CVD and requires ADT, then considering reducing duration of treatment may help mitigate risk.^{39,40} In addition, risk mitigation could include careful monitoring and control of modifiable risk factors such as blood pressure, cholesterol and diabetes and emphasis on exercise and cognitive behaviour strategies that have been used to mitigate negative metabolic consequences of ADT.^{23,41-44}

Since the introduction of newer LHRH antagonist medications as an option for ADT, research has begun exploring differences in

cardiovascular risk with more traditional LHRH agonists with some emerging evidence of reduced risk of CVD with the newer antagonists.^{34,45-48} In one post hoc analysis, the cardiac biomarker N-terminal pro-B-type natriuretic peptide (NTproBNP) at baseline was associated with increased risk of developing cardiovascular events in the LHRH agonist treatment arm but not the antagonist group.⁴⁹ These findings need further investigation but could offer a biomarker for clinicians to identify patients more suitable for treatment with an LHRH antagonist. Results are currently awaited from the PRO-NOUNCE trial, a large randomised trial of 545 people evaluating major cardiovascular events between LHRH agonist vs antagonist treated patients.⁵⁰

To summarise, in this unique study using registry-based data, there is evidence of an association between ADT for nonmetastatic PCa and a higher risk of CVD events, especially in those with some CVD risk factors present at the time of their diagnosis and longer duration of treatment. We also found higher all-cause mortality among patients receiving ADT. However, further studies with more detailed cancer data, specifically on cancer aggressiveness, are needed to determine the clinical relevance of these finding in context with overall benefit of ADT. Clinicians should carefully weigh the risks and benefits of ADT when developing a treatment plan, with possible consideration of early intervention for CVD risk factors.

AUTHOR CONTRIBUTIONS

Rachel B. Forster contributed to the conceptualisation of the study and development of the methodology, in addition to project administration and writing the original draft as well as review and editing the draft for submission. Anders Engeland was vital in the conceptualization of the project, data curation, formal analysis, as well as reviewing and editing of the manuscript. Rune Kvåle contributed to the conceptualization of the study, funding acquisition and supervision, as well as input in to methodology and reviewing and editing of the manuscript. Vidar Hjellvik contributed to funding acquisition, data curation, formal analysis, input in to methodology and reviewing and editing of the manuscript. Tone Bjørge was vital in conceptualisation of the study, funding acquisition, supervision as well as review and editing of the manuscript. The work reported in the paper has been performed by the authors, unless clearly specified in the text.

ACKNOWLEDGEMENTS

The study has used data from the Cancer Registry of Norway, the Norwegian Prescription Database and the Norwegian Patient Registry. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the registers is intended nor should be inferred.

CONFLICT OF INTEREST

The authors declare no potential conflict of interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of our study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

The study was approved by the Regional Committee for Medical and Health Research Ethics (REC South East; no. 2010/131). Individual consent to use registry data for our study was not required under the Norwegian Health Research Act of 2008.

ORCID

Rachel B. Forster  <https://orcid.org/0000-0002-7952-3570>

Anders Engeland  <https://orcid.org/0000-0001-5620-9207>

Rune Kvåle  <https://orcid.org/0000-0002-4106-230X>

Vidar Hjellvik  <https://orcid.org/0000-0002-2379-9906>

Tone Bjørge  <https://orcid.org/0000-0002-9096-5257>

TWITTER

Rachel B. Forster  @RachelBForster

REFERENCES

1. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami H-O. Temporal trends in cause of death among Swedish and US men with prostate cancer. *J Natl Cancer Inst.* 2012;104:1335-1342.
2. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. *J Clin Oncol.* 2010;28:3448-3456.
3. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin J-F, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. *Eur Urol.* 2011;60:1244-1250.
4. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a Nationwide Danish population-based cohort study. *Eur Urol.* 2014;65:704-709.
5. Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. *PLoS ONE.* 2014;9:e107516.
6. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. *J Clin Oncol.* 2006;24:4448-4456.
7. Nguyen PL, Je Y, Schutz FAB, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *JAMA.* 2011;306:2359-2366.
8. Wilcox C, Kautto A, Steigler A, Denham JW. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. *Oncology.* 2012;82:56-58.
9. Cereda V, Falbo PT, Manna G, et al. Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. *Heart Fail Rev.* 2020;27:119-134.
10. Kim DK, Lee HS, Park J-Y, et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study. *J Cancer Res Clin Oncol.* 2021;147:1217-1226.
11. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. *Br J Cancer.* 2014;110:551-555.
12. Hayes JH, Chen M-H, Moran BJ, et al. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. *BJU Int.* 2010;106:979-985.
13. Nanda A. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. *JAMA.* 2009;302:866.

14. Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. *Prostate Cancer Prostatic Dis.* 2019;22:24-38.
15. Mottet N, Cornford P, van den Bergh RCN, et al. *EAU Guidelines on Prostate Cancer.* Arnhem, The Netherlands: EAU Guidelines Office; 2021 ISBN 978-94-92671-13-4.
16. Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. *Eur Urol.* 2015;67:825-836.
17. Häppölä P, Havulinna AS, Tasa T, et al. A data-driven medication score predicts 10-year mortality among aging adults. *Sci Rep.* 2020;10:15760.
18. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. *Eur J Cancer.* 2009;45:1218-1231.
19. Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic cancer registries—an overview of their procedures and data comparability. *Acta Oncol.* 2018;57:440-455.
20. Wettermark B, Zoëga H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature review. *Pharmacoepidemiol Drug Saf.* 2013;22:691-699.
21. Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The Norwegian patient registry and the Norwegian registry for primary health care: research potential of two nationwide health-care registries. *Scand J Public Health.* 2020;48:49-55.
22. Davis MK, Rajala JL, Tyldesley S, Pickles T, Virani SA. The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada. *J Oncol.* 2015;2015:820403.
23. Sun L, Parikh RB, Hubbard RA, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. *JAMA Netw Open.* 2021;4:e210070.
24. Prostatakreft. *Nasjonalt handlingsprogram med retningslinjer for diagnose, behandling og oppfølging.* Oslo, Norway: Helsedirektoratet; 2020.
25. Tae BS, Jeon BJ, Choi H, Bae JH, Park JY. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study. *Cancer Med.* 2019;8:4475-4483.
26. Suissa S. Immortal time bias in Pharmacoepidemiology. *Am J Epidemiol.* 2008;167:492-499.
27. Hernes E, Kyrdalen A, Kvåle R, et al. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. *BJU Int.* 2010;105:805-811.
28. O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. *J Clin Oncol.* 2015;33:1243-1251.
29. Wu SY, Fang SC, Hwang OR, Shih HJ, Shao YJ. Influence of baseline cardiovascular comorbidities on mortality after androgen deprivation therapy for metastatic prostate cancer. *Cancers (Basel).* 2020;12:189.
30. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? *Eur Urol.* 2013;64:159-166.
31. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. *Urology.* 2008;71:318-322.
32. Morgans AK, Shore N, Cope D, et al. Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. *Urol Oncol Semin Orig Investig.* 2021;39:52-62.
33. Ng C-F, Chiu PKF, Yee C-H, Lau BSY, Leung SCH, Teoh JYC. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. *Sci Rep.* 2020;10:18060.
34. Lifshitz K, Ber Y, Shenhar C, et al. Cardiovascular proteomics: a post-hoc analysis from a phase II randomized clinical trial comparing GnRH antagonist vs GnRH agonist among men with advanced prostate cancer. *J Urol.* 2021;206:952-959.
35. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. *Lancet Oncol.* 2011;12:451-459.
36. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer. *JAMA.* 2008;299:289-295.
37. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncol.* 2010;11:1066-1073.
38. Morgia G, Russo GI, Tubaro A, et al. Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU guidelines: results from a multicenter, cross-sectional analysis from the CHOslng Treatment for Prostate canCER (CHOICE) study. *Urology.* 2016;96:165-170.
39. Gong J, Payne D, Caron J, et al. Reduced cardiorespiratory fitness and increased cardiovascular mortality after prolonged androgen deprivation therapy for prostate cancer. *Cardiooncology.* 2020;2:553-563.
40. Schmid M, Sammon JD, Reznor G, et al. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. *BJU Int.* 2016;118:221-229.
41. Crawley D, Garmo H, Rudman S, et al. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. *BMJ Open.* 2018;8:e020787.
42. Keating NL, Liu P-H, O'Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. *Eur Urol.* 2014;65:816-824.
43. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. *J Clin Oncol.* 2003;21:1653-1659.
44. Taylor CLC, Demoor C, Smith MA, et al. Active for life after cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. *Psychooncology.* 2006;15:847-862.
45. Davey P, Kirby MG. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. *World J Urol.* 2021;39:307-315.
46. George G, Garmo H, Scailteux LM, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. *Int J Cancer.* 2021;148(9):2203-2211.
47. Perrone V, Degli Esposti L, Giacomini E, Veronesi C, Bliani V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. *Ther Clin Risk Manag.* 2020;16:393-401.
48. Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. *J Urol.* 2019;202:1199-1208.
49. Margel D, Ber Y, Peer A, et al. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. *Prostate Cancer Prostatic Dis.* 2021;24:177-185.
50. Slovin SF, Alexander T. *A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate*

Cancer and Cardiovascular Disease (PRONOUNCE); 2016. <https://www.clinicaltrials.gov/ct2/show/NCT02663908>. Accessed October 21, 2021.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Forster RB, Engeland A, Kvåle R, Hjellvik V, Bjørge T. Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer. *Int J Cancer*. 2022;1-11. doi:[10.1002/ijc.34058](https://doi.org/10.1002/ijc.34058)